TECH.NASDAQBio-techne CORP

Form 4: Bio-Techne CFO James Hippel Reports Changes in Beneficial Ownership

Sentiment:

SEC Form 4


James Hippel, CFO of Bio-Techne Corp, filed a Form 4 detailing changes in his beneficial ownership, including the acquisition of restricted stock units and stock options.

Summary

  • James Hippel, the CFO of Bio-Techne Corp, reported changes in his beneficial ownership of the company's securities.
  • The report includes details of stock options and restricted stock units (RSUs) held by Hippel.
  • Hippel directly owns 99,926 shares of Bio-Techne common stock.
  • He also holds various stock options with exercise prices ranging from $31.26 to $120.46, expiring between 2025 and 2030.
  • The report details the vesting schedules for the RSUs and stock options, some of which are performance-based.
  • On August 15, 2024, Hippel acquired 24,062 performance restricted stock units, 12,031 restricted stock units, and options to purchase 32,417 shares.
  • The filing was signed by Andrew Nick as Attorney-in-Fact for James Hippel on August 19, 2024.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions by an insider.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. They are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

  • Shareholders may be interested in the details of insider transactions as an indicator of management's view of the company's value.

Key Dates

DateDescription
08/09/2024Date of stock options (Right to Buy) with an exercise price of $31.26
08/15/2024Date of earliest transaction reported; Acquisition of performance restricted stock units, restricted stock units, and stock options.
08/19/2024Date of filing; Signature of Attorney-in-Fact for James Hippel.
08/08/2025Date of stock options (Right to Buy) with an exercise price of $44.33
08/07/2026Date of stock options (Right to Buy) with an exercise price of $47.6
08/05/2027Date of stock options (Right to Buy) with an exercise price of $66.97
08/06/2028Date of stock options (Right to Buy) with an exercise price of $120.46
08/15/2029Date of performance stock options (Right to Buy) with an exercise price of $94.52
08/15/2030Date of performance stock options (Right to Buy) with an exercise price of $84.61
08/15/2034Date of stock options (Right to Buy) with an exercise price of $74.91

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.